The Trump Presidency Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : The Trump Presidency

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: i-node who wrote (351571)	10/12/2025 4:29:30 PM
From: Wharf Rat	1 Recommendation Recommended By bentway Read Replies (1) of 356012

I didn't get an MMR; I was a freshman in college when it was released. I had measles, but not mumps or rubella. == "mRNA was first used en masse five years ago during the pandemic -- created in a panic" MRNA was first used 12 years ago, but I wouldn't call it "en masse". History of mRNA Vaccines Avantor avantorsciences.com › knowledge-center › h... Using mRNA as a therapeutic tool was first proposed in the early 1990s and became feasible in the early 2000s. The first clinical trial of an mRNA vaccine was conducted in 2008 to treat prostate cancer. That vaccine was developed to stimulate the patient's immune system to attack prostate cancer cells. The results of that trial were promising and paved the way for further research in mRNA vaccines. In 2013, the first mRNA vaccine was approved for use in humans. Provenge was designed to treat prostate cancer by using the patient's immune cells to attack cancer cells. This vaccine demonstrated the potential of mRNA technology to improve the immune system.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next